GMNN

Geminin (GMNN) is a cell-cycle-regulated inhibitor of DNA re-replication that licenses orderly genome duplication by binding and inhibiting the replication-licensing factor CDT1 (PMID:40455380). Its activity is controlled at the protein level: geminin carries an N-terminal destruction box near residue Met28 that targets it for anaphase-promoting complex (APC)-mediated degradation at the metaphase-anaphase transition, so the protein accumulates in S/G2/M and is cleared in G1 (PMID:26637980). This phase-specific proteolysis is sufficiently robust that truncated geminin retaining only its degradation signals can be used as a fluorescent biosensor to mark S/G2/M phases, and the geminin N-terminal degron has been exploited to restrict Cas9 activity to S/G2, biasing repair toward homology-directed repair (PMID:29899280). Two distinct gain-of-function disease mechanisms have been defined: mutations that delete the destruction box stabilize geminin and prolong replication inhibition, causing autosomal-dominant Meier-Gorlin syndrome (PMID:26637980), whereas missense mutations that weaken the geminin-CDT1 interaction activate CHK1, induce DNA damage, and arrest preimplantation embryos (PMID:40455380).

1. 2015 Medium

   Established that geminin's abundance is set by APC recognition of an N-terminal destruction box, and that loss of this degron is a disease-causing gain-of-function mechanism rather than a loss of function.

   Evidence Human genetics identifying de novo destruction-box-disrupting mutations combined with cell-cycle phase and protein-stability analysis

   PMID:26637980

   Open questions at the time

   • Does not directly reconstitute APC-geminin recognition in vitro
   • Penetrance and tissue-specific consequences of stabilized geminin not resolved
2. 2018 Medium

   Demonstrated that the geminin N-terminal degron is portable and confers cell-cycle-restricted stability on a heterologous protein, confirming the degron is autonomous and functional out of context.

   Evidence Cas9-GMNN N-terminal peptide fusion in porcine fibroblasts with HDR knock-in frequency readout

   PMID:29899280

   Open questions at the time

   • Single cell type and single readout
   • Does not map the minimal degron residues required
3. 2025 Medium

   Defined the CDT1-binding interface as the functional output of geminin, showing that weakened geminin-CDT1 binding triggers CHK1 activation, DNA damage, and embryo arrest.

   Evidence Whole-exome/Sanger sequencing of patients, RNA-seq of zygotes/one-cell embryos, CDT1 binding assay, and CHK1/DNA-damage marker assessment

   PMID:40455380

   Open questions at the time

   • Single lab; binding deficit not structurally mapped
   • Causal chain from reduced binding to CHK1 activation inferred from markers, not dissected step-by-step
4. 2025 Medium

   Confirmed that geminin proteolysis is phase-specific and reciprocal to CDT1 degradation, validating geminin as a live-cell reporter of S/G2/M.

   Evidence Fucci(CA) fluorescent truncated-GMNN biosensor in a transgenic chicken line with in vitro and in vivo live imaging (preprint)

   Open questions at the time

   • Preprint, single study
   • Uses truncated protein retaining only degradation signals, not full-length geminin function

• How geminin-CDT1 binding affinity, geminin abundance, and APC-mediated turnover are quantitatively coordinated to enforce single-round replication remains unresolved.
• No structural model of the geminin-CDT1 or geminin-APC interaction in the corpus
• Direct biochemical reconstitution of CDT1 inhibition by geminin not present
• Tissue-specific thresholds linking degron/binding defects to distinct phenotypes unknown